Stella Pharma Corporation
4888.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.19B
Close$
Share Statistics
| Market cap | $14.19 Billion |
|---|---|
| Enterprise Value | $11.29 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.95 |
| Beta | 0.3 |
| Outstanding Shares | 34,952,718 |
Return
| Return on Equity | -26.51% |
|---|---|
| Return on Assets | -15.82% |
| Return on Invested Capital | -16.72% |
Valuation & Multiples
| P/E Ratio | -15.83 |
|---|---|
| PEG | -34.38 |
| Price to Sales | 43.78 |
| Price to Book Ratio | 4.28 |
| Enterprise Value to Revenue | 34.91 |
| Enterprise Value to EBIT | -13.11 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Stella Pharma Corporation
47 employees
CEO: Koki Uehara Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron ca...